Streetbeat News

Products Services

PATH

UiPath has announced a new integration service connector that will give its customers access to Amazon Bedrock. This move is expected to enhance the company's automation capabilities and expand its customer base.

Portfolio Pulse from Bill Haddad

October 09, 2023 | 12:06 pm

MREO

RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Mereo BioPharma Group plc (NASDAQ:MREO) will present new data from the Phase 2/3 Orbit study of setrusumab in osteogenesis imperfecta (OI) at the American Society for Bone and Mineral Research 2023 Annual Meeting. The data includes updated results on annualized clinical fracture rate in patients aged 5 to <26 years, and data on the burden of fractures for individuals living with OI. The companies previously announced positive data from the dose-selection Phase 2 portion of the Orbit study showing that setrusumab rapidly induced bone production in OI-affected patients.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:04 pm

COYA

Coya Therapeutics has completed enrollment for a Phase 2 study of low dose Interleukin-2 (LD IL-2) in patients with Alzheimer's Disease. The study, funded by the Gates Foundation and Alzheimer's Association, will evaluate the safety, tolerability, and preliminary efficacy of LD IL-2 in 38 patients over 30 weeks. Previous data showed significant improvement in cognitive function with LD IL-2 treatment. Coya's proprietary LD IL-2 (COYA 301) is being developed as a treatment for Alzheimer's and in combination with CTLA4 Ig (COYA 302) for Amyotrophic Lateral Sclerosis (ALS).

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:03 pm

ELOX

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) reported positive biopsy results from a Phase 2 clinical trial of ELX-02 for the treatment of Nonsense Mutation Alport syndrome patients. The results, assessed by NIPOKA GmbH, confirm that ELX-02 treatment improved podocyte foot process morphology with lower effacement in all three patients at the end of the 8-week study period.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:02 pm

OST

Ostin Technology Group Co. (NASDAQ:OST) has secured new purchase orders for nearly 5,000 treadmill screen products from a leading fitness equipment manufacturer in China. The company also announced the opening of its flagship Douyin store, where its M4 and GT8-PRO smartwatches are now available for purchase. The company plans to leverage Chinese short-video platforms to boost sales and expects to showcase its smartwatches on other platforms like Kuaishou and WeChat Channel within the year.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:02 pm

AQST

Aquestive Therapeutics has received comments from the FDA on its Phase 3 pharmacokinetic study protocol for Anaphylm (Epinephrine) Sublingual Film. The FDA indicated that the company's proposed endpoints, sample size, and statistical analysis are reasonable.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:02 pm

JSPR

Jasper Therapeutics has received IND clearance for a Phase 1b/2a study of subcutaneous Briquilimab in Chronic Spontaneous Urticaria. The study will enroll around 40 patients across 6 cohorts, focusing on safety, tolerability, efficacy measures, and pharmacokinetics of Briquilimab.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:02 pm

ANAB

AnaptysBio, Inc. (NASDAQ:ANAB) announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab in patients with generalized pustular psoriasis (GPP). The trial met its primary endpoint with 53.3% of patients achieving clear or almost clear skin at Week 4 after a single dose of 750mg IV imsidolimab, compared to 13.3% of patients on placebo. The company plans to present comprehensive data from GEMINI-1 and top-line GEMINI-2 results at a medical meeting in H2 2024 and intends to out-license imsidolimab in 2024.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2023 | 12:01 pm

MLRT

MetAlert, Inc (OTC:MLRT) has received and delivered its first commercial order for the GunAlert firearm recovery device from Range USA. The device, developed by MetAlert's subsidiary Level 2 Security, uses motion detection and GPS technology to monitor unauthorized use and movement of firearms. The company plans to work with law enforcement and media to promote the technology.

Portfolio Pulse from Anusuya Lahiri

October 09, 2023 | 12:00 pm

BBY

Best Buy Co Inc (NYSE:BBY) will start selling the Dexcom G7 Continuous Glucose Monitoring System (CGM) online, marking its first foray into prescription-based medical devices. The sale will be facilitated by Wheel, a virtual care platform, and HealthDyne, a pharmacy technology provider. This move aligns with Best Buy Health's goal to facilitate care at home.

Portfolio Pulse from Shivani Kumaresan

October 09, 2023 | 11:54 am